Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?
- DOI
- 10.1016/j.jdiacomp.2026.109418
- Published
- 2026-09
- Container
- Journal of Diabetes and its Complications
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jdiacomp.2026.109418,
title = {Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?},
author = {Dimitrios Patoulias and Emir Muzurović and Manfredi Rizzo and Christos S. Mantzoros},
year = {2026},
journal = {Journal of Diabetes and its Complications},
doi = {10.1016/j.jdiacomp.2026.109418},
url = {https://doi.org/10.1016/j.jdiacomp.2026.109418}
}RIS
TY - JOUR TI - Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease? AU - Dimitrios Patoulias AU - Emir Muzurović AU - Manfredi Rizzo AU - Christos S. Mantzoros PY - 2026 JO - Journal of Diabetes and its Complications DO - 10.1016/j.jdiacomp.2026.109418 UR - https://doi.org/10.1016/j.jdiacomp.2026.109418 ER -
APA
Patoulias, D., Muzurović, E., Rizzo, M., & Mantzoros, C. S. (2026). Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?. Journal of Diabetes and its Complications. https://doi.org/10.1016/j.jdiacomp.2026.109418
Source records
- crossref · retrieved 2026-09-26T20:47:32.082Z